Evidence map›Paper›PMID 29057162›Full record

ArticleTranslational vision science & technology2017

Augmenting Endogenous Levels of Retinal Annexin A1 Suppresses Uveitis in Mice.

Peter J Gardner, Samia Yazid, Joana Ribeiro, Robin R Ali, Andrew D Dick

Open access · goldAbstract read
In one paragraph

Article in Translational vision science & technology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Annexin A1 in the nervous and ocular systems.Neural regeneration research · 2024
    Review
  6. Resolution of Inflammation in Retinal Disorders: Briefly the State.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Peter J GardnerUCL Institute of Ophthalmology, London, UK.
Samia YazidTrio Medicines Ltd., London, UK.
Joana RibeiroUCL Institute of Ophthalmology, London, UK.
Robin R AliUCL Institute of Ophthalmology, London, UK.
Andrew D DickUCL Institute of Ophthalmology, London, UK.
University College London · GBMoorfields Eye Hospital NHS Foundation Trust · GBTrio Medicines (United Kingdom) · GB

Funding

Medical Research Council MR/L012758/1
6 · The paper itself

Abstract

purposeThe purpose of this study was to examine the expression of the anti-inflammatory protein Annexin A1 (AnxA1) in mice and human retinae during uveitis and to determine whether local administration of human recombinant AnxA1 (hrAnxA1) can suppress uveitis in mice.

methodsRetinal sections from mice (healthy normal and uveitis) and postmortem human (no history of eye disease (

resultsConstitutive expression of AnxA1 was observed in both healthy mouse and human retinae, and its expression increased during uveitis compared to healthy controls. AnxA1 colocalizes predominantly with CD45

conclusionsThese data indicate that locally expressed AnxA1 is elevated in the retina during intraocular inflammation. We demonstrate that local administration of hrAnxA1 to augment levels results in suppression of uveitis in mice. TRANSLATIONAL RELEVANCE: Our data suggest that elevated expression of retinal AnxA1 in human uveitis may be immunoregulatory and that local supplementation with hrAnxA1 may provide a potential novel treatment for inflammatory eye diseases such as noninfectious uveitis.

Indexed as

Annexin A1endotoxin-induced uveitisexperimental autoimmune uveitisinflammationuveitis

Identifiers

PMID29057162
PMCPMC5648521
OpenAlexW2760896838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.